Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 2/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | THPO | P40225 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.46 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.46 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7091169 | 0.95 | ADORA2B (0.48) | ADORA2BADORA1ADORA2AKDM4EALDH1A1 | |
| SCHEMBL3229725 | 0.94 | ADORA2A (0.47) | ADORA2BADORA1ADORA2A | |
| SCHEMBL7093461 | 0.90 | P2RX3 (0.41) | ADORA2BADORA1ADORA2AKDM4EALDH1A1 | |
| SCHEMBL7955639 | 0.89 | ADORA2A (0.42) | ADORA2BADORA1ADORA2A | |
| SCHEMBL7091149 | 0.87 | P2RX3 (0.41) | ADORA2BADORA1ADORA2AKDM4EALDH1A1 | |
| SCHEMBL7953405 | 0.85 | ADORA2A (0.41) | ADORA2BADORA1ADORA2AALDH1A1HPGD | |
| SCHEMBL7953326 | 0.84 | SIRT1 (0.61) | ADORA2BADORA1ADORA2AKDM4EALDH1A1 | |
| SCHEMBL7091342 | 0.83 | KDM4E (0.42) | ADORA2BADORA1ADORA2AKDM4EALDH1A1 | |
| SCHEMBL7955637 | 0.83 | SIRT1 (0.54) | ADORA2BADORA1ADORA2AKDM4EALDH1A1 | |
| SCHEMBL3231585 | 0.83 | ADORA2A (0.57) | ADORA2BADORA1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2146996-A1 | XANTHINE COMPOUNDS HAVING A POSITIVE ALLOSTERIC GABAB RECEPTOR MODULATOR EFFECT | AstraZeneca AB (SE) | 2010-01-27 | — | — | EP | claimed |
| US-20090023704-A1 | Novel Compounds 737 | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | claimed |
| WO-2008130314-A1 | XANTHINE COMPOUNDS HAVING A POSITIVE ALLOSTERIC GABAB RECEPTOR MODULATOR EFFECT | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | WO | claimed |
| EP-2146996-A1 | XANTHINE COMPOUNDS HAVING A POSITIVE ALLOSTERIC GABAB RECEPTOR MODULATOR EFFECT | AstraZeneca AB (SE) | 2010-01-27 | — | — | EP | disclosed |
| US-20090023704-A1 | Novel Compounds 737 | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
| WO-2008130314-A1 | XANTHINE COMPOUNDS HAVING A POSITIVE ALLOSTERIC GABAB RECEPTOR MODULATOR EFFECT | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | WO | disclosed |
| EP-0799040-B1 | TRISUBSTITUTED THIOXANTHINES | EURO CELTIQUE SA (LU) | 2003-08-20 | — | — | EP | disclosed |
| US-6268373-B1 | ENZYME INHIBITORS | EURO-CELTIQUE S.A. (LU) | 2001-07-31 | — | — | US | disclosed |
| US-6025361-A | EFFECTIVE PDE IV INHIBITORS, ASTHMA | EURO-CELTIQUE, S.A. (LU) | 2000-02-15 | — | — | US | disclosed |
| US-5977119-A | Trisubstituted thioxanthines | EURO-CELTIQUE, S.A. (LU) | 1999-11-02 | — | — | US | disclosed |
| EP-0799040-A4 | TRISUBSTITUTED THIOXANTHINES | EURO CELTIQUE SA (LU) | 1998-04-01 | — | — | EP | disclosed |
| EP-0799040-A1 | TRISUBSTITUTED THIOXANTHINES | Euroceltique S.A. (LU) | 1997-10-08 | — | — | EP | disclosed |
| WO-1996018400-A1 | TRISUBSTITUTED THIOXANTHINES | EURO-CELTIQUE, S.A. (LU) | 1996-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023704-A1 | Novel Compounds 737 | GRPR, GABRB1, GABBR1 | ADORA2B 130/4885ADORA1 164/4885ADORA2A 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.